Markets By TradingView

Pfizer Continues to Earn!

Earn-Are you looking for an extra income in the market? If yes, the first stock that comes to mind is of course Pfizer.

Pfizer Continues to Earn!
Yazar: Ross Sutton

Yayınlanma: 10 Haziran 2021 15:48

Güncellenme: 28 Mart 2024 01:23

Pfizer Continues to Earn!

  Pfizer Continues to Earn! Earn-Are you looking for an extra income in the market? If yes, the first stock that comes to mind is of course Pfizer. “The thing that gives me the most joy is seeing the returns on my dividends.” If we take John D. Rockefeller as a reference, high-yielding dividend stocks may not always be a safe investment. Dividends can sometimes herald that the company is in trouble or an upcoming dividend cut. This is exactly why you choose high-quality, high-yielding dividend stocks to add to your portfolio. After all, there are a few safe and attractive high-yielding dividend stocks in today's market, one of which is Pfizer (NYSE:PFE)

Pfizer is a Dividend King

It is one of the pharmaceutical companies that has dominated the market for years with a long-established business of 172 years and a very hard working principle. Finally, it started to distribute it globally by producing a successful COVID-19 vaccine with its German partner BioNTech. With sales from both the vaccine and its essential drugs, Pfizer has the financial momentum behind it. The company earned $3.46 billion from the COVID-19 vaccine alone in the first quarter of 2021. With sales from both the vaccine and its essential drugs, Pfizer has the financial momentum behind it. The company earned $3.46 billion from the COVID-19 vaccine alone in the first quarter of 2021.

Earn-Are you looking for an extra income in the market? If yes, the first stock that comes to mind is of course Pfizer.

Clearly, the vaccine isn't the only bright spot for Pfizer, the growth from its key drugs is also very encouraging. Some of these drugs are as follows; - Eliquis (for anti-clotting), - Vyndamax (for heart problems) and - Xeljanz. (for rheumatoid arthritis) Sales in the first quarter increased 25 %, 88 % and 18 %, respectively, year-on-year. The combination of these three drugs brought Pfizer more than $2,5 billion in revenue in the first quarter alone. Pfizer Equity remains one of the best opportunities for income-seeking investors. The company, which showed a great increase compared to last year, offers a dividend yield of 4 % this year. This rate is a very attractive offer for investors who want to earn more.  

Source: The Motley Fool

 

You may also be interested in:

 

Why Are Bitcoin Mining Stocks Soaring?

En Popüler Haberler

Yorum Yap

Yazılan yorumlar hiçbir şekilde Son Ekonomi Haberleri - Türkiye Dünya - ieconomy.io görüş ve düşüncelerini yansıtmamaktadır. Yorumlar, yazan kişiyi bağlayıcı niteliktedir.

Yorumlar

Henüz yorum yapan yok! İlk yorumu siz yapın...

Borsa, Kripto, Hisse, Emtia ve Döviz Haberleri

ieconomy: Türkiye'nin en kapsamlı ekonomi haber sitesi. Son dakika haberleri ve en güncel haberler ieconomy'da.